Every Form 4 that Jazz Pharmaceuticals, Inc. (JAZZ) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow JAZZ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full JAZZ filings page.
Jazz Pharmaceuticals SVP and Chief Accounting Officer Patricia Carr reported two share dispositions. On March 9, 2026, she completed an open-market sale of 1,287 ordinary shares at a weighted average price of $182.94, leaving 6,512 shares directly owned afterward.
On March 5, 2026, she disposed of 1,436 ordinary shares at $186.7723 per share to satisfy tax obligations arising from the vesting of previously granted restricted stock units, resulting in 7,799 shares directly owned following that transaction.
Jazz Pharmaceuticals plc President & CEO Renee D. Gala reported a tax-related share transaction. On March 5, 2026, 7,065 ordinary shares were disposed of at $188.69 per share to satisfy tax obligations from vesting restricted stock units. After this withholding transaction, she directly owned 152,630 ordinary shares.
Jazz Pharmaceuticals plc executive Neena M. Patil, EVP & Chief Legal Officer, reported a tax-related share disposition. On March 5, 2026, 5,000 Ordinary Shares of Jazz were withheld at $188.69 per share to satisfy tax obligations from the vesting of previously granted restricted stock units. This was recorded as a tax-withholding disposition rather than an open-market sale, and Patil’s directly held stake after the transaction was 53,818 Ordinary Shares.
Jazz Pharmaceuticals director Bruce C. Cozadd reported selling a total of 6,000 ordinary shares of JAZZ in open-market transactions on March 3, 2026. The sales occurred in three blocks at weighted average prices of $186.0853, $186.7340 and $187.8444, executed under a Rule 10b5-1 trading plan. Following these planned sales, Cozadd directly owns 405,796 ordinary shares of Jazz Pharmaceuticals.
Jazz Pharmaceuticals director Norbert G. Riedel exercised stock options and sold shares on ordinary shares. On February 27, 2026, he exercised a non-qualified stock option for 3,415 shares, converting it into the same number of ordinary shares at an exercise price of $138.08 per share.
On the same date, he then sold 3,415 ordinary shares in an open-market transaction at $192.00 per share, leaving him with 7,024 ordinary shares held directly. A separate indirect position of 10,630 ordinary shares is reported as held by a trust.
Johnson Philip L reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals executive vice president and chief financial officer Philip L. Johnson reported an equity grant of 11,857 restricted stock units, each representing one ordinary share, awarded at no cash cost under the company’s 2011 Equity Incentive Plan.
The units vest in four equal annual installments starting on March 5, 2026, with one-quarter vesting on the first anniversary of that date and the remainder vesting annually over the next three years. Following this award, Johnson directly holds 62,223 ordinary shares.
Jazz Pharmaceuticals plc executive Samantha Pearce, EVP and Chief Commercial Officer, received an equity award tied to the company’s ordinary shares. She acquired 9,782 restricted stock units, with no cash paid per share, increasing her directly held stake to 52,775 ordinary shares after the transaction.
Each restricted stock unit represents a right to receive one ordinary share if it vests under the company’s 2011 Equity Incentive Plan. The award vests in four equal annual installments starting on March 5, 2026, with one-quarter vesting on the first anniversary of that date and the remainder vesting annually over the following three years.
Jazz Pharmaceuticals reported that EVP and Global Head of R&D and CMO Robert Iannone acquired 14,822 ordinary shares through a stock-based award at no cost. The grant consists of restricted stock units that convert into one ordinary share each as they vest.
The units vest in four equal annual installments starting on March 5, 2026, with one-quarter vesting on the first anniversary and the remainder over the following three years. After this award, Iannone directly holds 95,080 ordinary shares.
Jazz Pharmaceuticals SVP and Chief Accounting Officer Patricia Carr reported a mix of share awards and sales. On February 26, 2026, she received a grant of 2,223 restricted stock units under the company’s 2011 Equity Incentive Plan, with each unit convertible into one ordinary share. These units vest in equal annual installments over four years starting on March 5, 2026.
Also on February 26, 2026, she executed an open-market sale of 1,253 ordinary shares at a weighted average price of $194.1119, in multiple trades between $193.7300 and $194.4100, and shares were sold to satisfy tax obligations from vesting restricted stock units. On February 27, 2026, she sold an additional 1,117 ordinary shares at an average price of $190.9073. After these transactions, she directly held 9,235 ordinary shares.
GALA RENEE D reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals plc reported that President & CEO Renee D. Gala received an equity grant of 44,465 restricted stock units under the company’s 2011 Equity Incentive Plan. Each unit represents a right to receive one ordinary share when it vests.
The grant vests in four equal annual installments starting on March 5, 2026, with one-quarter vesting on the first anniversary of that date and the remaining three-quarters vesting in equal annual installments over the following three years. After this award, she directly holds 159,695 ordinary shares.
LOVE TED W reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals plc director Ted W. Love reported receiving a grant of 1,527 ordinary shares in the form of restricted stock units. The award was made at a price of $0.00 per share, reflecting an equity compensation grant rather than a market purchase.
Each restricted stock unit represents the right to receive one ordinary share if certain conditions are met. The units are scheduled to vest in full on July 24, 2026, subject to Dr. Love’s continuous service and additional plan conditions. Following this grant, he holds 1,527 ordinary shares directly.
Jazz Pharmaceuticals EVP & Chief Legal Officer Neena M. Patil reported a mix of stock option exercises, share sales, and equity awards. She exercised multiple incentive and non-qualified stock options into ordinary shares and sold a total of 55,600 ordinary shares in open-market transactions at weighted average prices generally around $190–$193 per share. Patil also acquired 10,079 restricted stock units granted under the 2011 Equity Incentive Plan, which vest in equal annual installments over four years starting on March 5, 2026. Following these transactions, she directly owns 58,818 ordinary shares of Jazz Pharmaceuticals.
Jazz Pharmaceuticals senior vice president of Technical Operations Mary Elizabeth Henderson reported both an equity award and a share sale. She received 4,447 ordinary shares as a restricted stock unit grant at a price of $0.00 per share under the company’s 2011 Equity Incentive Plan. These units vest in four equal annual installments starting on March 5, 2026, with one-quarter vesting each year over four years. On the same date, she sold 5,343 ordinary shares in open-market transactions at a weighted average price of $194.4852 per share, in multiple trades between $194.1900 and $194.5000. According to the filing, these shares were sold to satisfy tax obligations arising from the vesting of previously granted restricted stock units, and she held 28,728 ordinary shares directly following the sale.
Jazz Pharmaceuticals plc executive Mary Elizabeth Henderson reported an equity award vesting. On January 16, 2026, she acquired 10,116 ordinary shares of Jazz Pharmaceuticals at a stated price of $0.0 per share. These shares relate to performance share awards originally granted on March 3, 2023, with the performance-based vesting conditions certified as achieved on January 16, 2026.
Following this transaction, Henderson beneficially owns 29,624 ordinary shares in total, held directly. She serves as SVP, Technical Operations at Jazz Pharmaceuticals. The Form 4 indicates this is a non-derivative acquisition tied to prior performance awards rather than an open-market purchase.
Jazz Pharmaceuticals executive Patricia Carr, who serves as SVP and Chief Accounting Officer, reported an acquisition of company stock. On January 16, 2026, she acquired 2,370 ordinary shares at a price of $0.0 per share. These shares will be delivered under performance share awards originally granted on March 3, 2023, after the company certified that the performance-based vesting requirements were satisfied on January 16, 2026. Following this award vesting, Carr now directly beneficially owns 9,382 ordinary shares of Jazz Pharmaceuticals.
Jazz Pharmaceuticals’ EVP & Chief Legal Officer Neena M. Patil reported equity compensation activity in the company’s ordinary shares. On January 16, 2026, she received 8,852 ordinary shares at $0.0 per share upon vesting of performance share awards that were originally granted on March 3, 2023, after performance goals were certified as achieved.
On the same date, 3,275 ordinary shares were disposed of at $171.16 per share, with the filing explaining these shares were withheld from the vesting and distribution of the performance awards to satisfy her tax obligations. After these transactions, she directly beneficially owned 53,339 ordinary shares of Jazz Pharmaceuticals.
Jazz Pharmaceuticals executive Samantha Pearce reported equity award activity in Jazz (JAZZ) shares. On January 16, 2026, she acquired 3,637 ordinary shares at a price of $0.0, delivered under performance share awards originally granted on March 3, 2023, after performance-based vesting requirements were certified as satisfied on that date.
Also on January 16, 2026, 1,599 ordinary shares were withheld at $171.16 per share to cover her tax obligations arising from the vesting and distribution of those performance share awards. After these transactions, she directly owned 42,993 ordinary shares of Jazz Pharmaceuticals. A footnote notes that she had previously acquired 140 ordinary shares under a Section 423 employee stock purchase plan on November 28, 2025.
Jazz Pharmaceuticals executive Robert Iannone reported equity compensation activity involving the company’s ordinary shares. On January 16, 2026, he received 11,699 ordinary shares at a price of $0.00 per share, delivered upon the vesting of performance share awards that were granted on March 3, 2023 after performance was certified. On the same date, 4,140 ordinary shares were withheld at $171.16 per share to cover his tax obligations related to the vesting and distribution of those awards.
Following these transactions, Iannone directly beneficially owned 80,258 ordinary shares of Jazz Pharmaceuticals. The filing also notes that he previously acquired 71 ordinary shares under a Section 423 employee stock purchase plan on November 28, 2025.
Jazz Pharmaceuticals plc President & CEO Renee D. Gala reported changes in her holdings of ordinary shares tied to performance-based equity awards. On January 16, 2026, she received 12,741 ordinary shares at a price of $0.00 per share, delivered upon the vesting of performance share awards that were originally granted on March 3, 2023, after performance was certified as achieved.
On the same date, 5,371 ordinary shares were withheld at a price of $171.16 per share to cover her tax obligations related to the vesting and distribution of these performance share awards. Following these transactions, Gala directly beneficially owns 115,230 ordinary shares of Jazz Pharmaceuticals.
Jazz Pharmaceuticals plc director Bruce C. Cozadd reported equity compensation and related tax withholding transactions in the company’s ordinary shares. On January 16, 2026, he received 35,917 ordinary shares at $0.0 per share, delivered under performance share awards that were originally granted on March 3, 2023 and certified as having met their performance-based vesting requirements on that date.
Also on January 16, 2026, 17,453 ordinary shares were disposed of at a price of $171.16 per share, with the filing explaining that these shares were withheld from the vesting and distribution of the performance share awards to satisfy his tax obligations. Following these transactions, Cozadd directly beneficially owned 411,796 ordinary shares of Jazz Pharmaceuticals.
Jazz Pharmaceuticals plc director Patrick Enright reported a transfer of 5,000 Ordinary Shares on 08/18/2025. The Form 4 shows this was a code J transaction, with a footnote explaining the shares were transferred to a former spouse without any payment as part of a comprehensive division of marital assets. After this transfer, Enright beneficially owned 21,379 Ordinary Shares, held directly.
Jazz Pharmaceuticals plc disclosed that senior vice president of technical operations Mary Elizabeth Henderson sold 2,238 ordinary shares on 12/09/2025. The transaction was reported with code "S" for an open-market or private sale at a weighted average price of $169.511, with individual trades executed between $169.00 and $169.82. Following these sales, she directly beneficially owns 19,508 ordinary shares of Jazz Pharmaceuticals.
Jazz Pharmaceuticals (JAZZ) director Heather McSharry reported an option exercise and share sale. On 11/20/2025 she exercised 3,415 non-qualified stock options at an exercise price of $138.08 per share, acquiring the same number of ordinary shares.
On the same date, she sold 3,415 ordinary shares at a price of $177.7823 per share. After these transactions, she directly beneficially owned 20,449 ordinary shares of Jazz Pharmaceuticals. The exercised options were originally granted in August 2016, fully vested by August 2017, and were scheduled to expire on 08/10/2026.
Jazz Pharmaceuticals senior vice president of technical operations Mary Elizabeth Henderson reported a sale of company stock in connection with equity compensation. On 11/19/2025, she disposed of 1,331 ordinary shares of Jazz Pharmaceuticals plc at a price of $180.4 per share, as shown in Table I of the filing. The filing states that these shares were sold to cover tax obligations from the vesting of previously granted restricted stock units, which is a common administrative transaction for equity awards. After this sale, she beneficially owned 21,746 ordinary shares, held directly.
Jazz Pharmaceuticals plc director reports share sales and RSU grant. A board member of Jazz Pharmaceuticals filed a Form 4 disclosing several open-market sales of ordinary shares on November 18, 2025 at weighted average prices ranging from $180.0859 to $182.6009. Following these transactions, the reporting person directly beneficially owned 390,826 ordinary shares.
On November 20, 2025, the director received 2,506 restricted stock units at a price of $0.0 under Jazz’s 2007 Amended and Restated Non-Employee Directors Stock Award Plan, increasing direct beneficial ownership to 393,332 ordinary shares. Each unit represents a contingent right to one ordinary share and, subject to continuous service and certain additional conditions, will vest in full on July 24, 2026.
Jazz Pharmaceuticals (JAZZ) insider Patricia Carr, SVP and Chief Accounting Officer, reported option-related share transactions. On November 18, 2025, she exercised a non-qualified stock option covering 5,250 ordinary shares at an exercise price of $136.18 per share, increasing her direct shareholdings. On the same date, she reported two sales of ordinary shares: one for 69 shares at $181.66 per share and another for 5,250 shares at $182.07 per share. After these transactions, she directly owned 7,012 ordinary shares of Jazz Pharmaceuticals.
Jazz Pharmaceuticals plc (JAZZ) director Rick E. Winningham reported a sale of company stock. On 11/18/2025, he sold 5,500 ordinary shares of Jazz Pharmaceuticals at a price of $180.8597 per share. After this transaction, he beneficially owned 8,893 ordinary shares, held directly. This filing is a routine disclosure of insider trading activity required under securities regulations.
Jazz Pharmaceuticals plc executive Robert Iannone, EVP, Global Head of R&D & CMO, reported a stock sale in a Form 4 filing. On 11/17/2025, he sold 7,159 ordinary shares of JAZZ at $168.26 per share in a transaction carried out under a pre-arranged Rule 10b5-1 trading plan. After this sale, he beneficially owned 72,628 ordinary shares. A footnote notes that he had previously acquired 166 ordinary shares on May 30, 2025 under a Section 423 Employee Stock Purchase Plan.
Bruce C. Cozadd, a director of Jazz Pharmaceuticals plc (JAZZ), reported two open-market sales under a Rule 10b5-1 trading plan. On 10/01/2025 he sold 2,000 ordinary shares at $131.78, reducing his beneficial holdings to 412,326 shares. On 10/03/2025 he sold an additional 3,500 shares at $140.00, reducing holdings to 408,826 shares. The Form 4 is signed by an attorney-in-fact and notes the transactions were executed pursuant to the disclosed 10b5-1 plan.